IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Atara Biotherapeutics Inc (ATRAGBX)

CUSIP: 046513107 | X1 | 444 institutional holders

Quarters

Q2 2026Q1 2026Q3 2025Q4 2024Q3 2024
CompareDetailedHistoricalFundsOptions13D/13GPeersTargetingTrading SummaryProfile

Beneficial Ownership — 13D / 13G

Full history →

5%+ stakes reported outside the quarterly cycle. A 13D is due within five business days of the event below, so these figures lead the holders table until the filer's next 13F catches up to them.

HolderShares% of ClassChangeEvent Datevs 13F
13D/APanacea Innovation Limited
with Panacea Venture Healthcare Fund II, L.P., Panacea Venture Healthcare Fund II GP Company, Ltd., Panacea Opportunity Fund I, L.P., +1 more
1,318,89416.1%−313,451May 7, 2026No 13F filer matched
13D/APanacea Innovation Limited1,318,894
16.1% of class · May 7, 2026−313,451
with Panacea Venture Healthcare Fund II, L.P., Panacea Venture Healthcare Fund II GP Company, Ltd., Panacea Opportunity Fund I, L.P., +1 more
No 13F filer matched

Institutional Holders — Q2 2026

PlanVest Financial, Inc28
0.0% of portfolio›$321
StyleTurnoverLocationFiled
PlanVest Financial, Inc
28$3210.0%ETFN/AGaithersburg, MD2026-08-10